[
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic. The analyst reiterated his Overweight rating on the stock, which offers a revised upside potential of […]",
    "url": "https://finnhub.io/api/news?id=ea30a22f662950b49a5fb122de9d68965a28ce843770500e905f66fb7e2ef14c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771879295,
      "headline": "Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery",
      "id": 139188019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic. The analyst reiterated his Overweight rating on the stock, which offers a revised upside potential of […]",
      "url": "https://finnhub.io/api/news?id=ea30a22f662950b49a5fb122de9d68965a28ce843770500e905f66fb7e2ef14c"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich",
    "summary": "\"Boring\" may be just what the doctor ordered in this volatile market.",
    "url": "https://finnhub.io/api/news?id=760c0ba33dad58d6bf54980e01ad0d716edbccbc40afc5b258fe8a896a42c6d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771878000,
      "headline": "Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich",
      "id": 139187912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "\"Boring\" may be just what the doctor ordered in this volatile market.",
      "url": "https://finnhub.io/api/news?id=760c0ba33dad58d6bf54980e01ad0d716edbccbc40afc5b258fe8a896a42c6d1"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting",
    "summary": "Exact Sciences (NASDAQ:EXAS) held a special meeting of stockholders on February 20, 2026, to vote on proposals related to its previously announced merger agreement with Abbott Laboratories. Kevin Conroy, chairman of Exact Sciences’ board of directors, presided over the virtual meeting. James Herriot",
    "url": "https://finnhub.io/api/news?id=770315f6f04b3a845edc5b3a134e209d93f547bd479461cb6515c779a581bd72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771866446,
      "headline": "Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting",
      "id": 139186471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences (NASDAQ:EXAS) held a special meeting of stockholders on February 20, 2026, to vote on proposals related to its previously announced merger agreement with Abbott Laboratories. Kevin Conroy, chairman of Exact Sciences’ board of directors, presided over the virtual meeting. James Herriot",
      "url": "https://finnhub.io/api/news?id=770315f6f04b3a845edc5b3a134e209d93f547bd479461cb6515c779a581bd72"
    }
  },
  {
    "ts": null,
    "headline": "Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say",
    "summary": "While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=1544657194bf4c37c786324b2e0bac44555b4be341ba51f7294f7180544b4f18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771857002,
      "headline": "Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say",
      "id": 139186472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=1544657194bf4c37c786324b2e0bac44555b4be341ba51f7294f7180544b4f18"
    }
  },
  {
    "ts": null,
    "headline": "Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions",
    "summary": "A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven deaths globally and hundreds of serious injuries among users. The suit alleges Abbott identified manufacturing problems in internal testing and did not disclose the defect until after a reported death. The case raises questions about product safety, regulatory oversight, and potential financial...",
    "url": "https://finnhub.io/api/news?id=ba045639f2f287ab727095a1d354139e6acaa440bb85d0ed56c18aa684bd4b8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771837915,
      "headline": "Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions",
      "id": 139182351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven deaths globally and hundreds of serious injuries among users. The suit alleges Abbott identified manufacturing problems in internal testing and did not disclose the defect until after a reported death. The case raises questions about product safety, regulatory oversight, and potential financial...",
      "url": "https://finnhub.io/api/news?id=ba045639f2f287ab727095a1d354139e6acaa440bb85d0ed56c18aa684bd4b8d"
    }
  }
]